Pomalyst (Pomalidomide)

Description

Pomalyst (Pomalidomide) is a third-generation immunomodulatory drug that can modify or regulate the functioning of the immune system. This medication is used to treat multiple myeloma and AIDS-related Kaposi sarcoma. It is typically taken in combination with another medicine, dexamethasone, to treat adults with multiple myeloma who have previously received at least 2 medicines, including a proteasome inhibitor and lenalidomide.

Directions

The initial dosage for adults with multiple myeloma is 4 milligrams (mg) once daily. It is typically taken on days 1 to 21 of a 28-day cycle, with this schedule repeated every 28 days. A healthcare provider may adjust this dosage as needed, based on tolerance and effectiveness. When taking Pomalyst, follow the directions on the prescription label carefully. If any part of the directions is unclear, consult a healthcare provider.

Ingredients

Pomalidomide is the active ingredient in Pomalyst. Along with the active ingredient, Pomalyst capsules may contain several inactive ingredients.

Contraindications

Pomalyst should not be used by pregnant women or women who may become pregnant during treatment. It is critical that patients using Pomalyst take appropriate measures to prevent pregnancy during their treatment and for four weeks after stopping the medication. In addition, Pomalyst may not be suitable for patients with a history of severe hypersensitivity reactions to the drug or its components.

Cautions

• Before starting Pomalyst, inform your healthcare provider of the following:
• Any health issues, particularly those related to liver or kidney function.
• If you use tobacco products.
• If you're expecting or nursing, as Pomalyst carries a high risk of causing serious harm to an unborn baby.
• Combining Pomalyst with specific drugs for multiple myeloma treatment can significantly increase health risks, so a detailed consultation with your doctor is necessary.
• Regular blood tests are crucial to monitor neutropenia, a condition of low white blood cells, which can arise during treatment.
• Patients may experience liver issues, even failure, so monthly liver function tests are recommended to detect any problems early.
• Discontinue Pomalyst at once if severe skin reactions occur, and seek immediate medical advice.
• High tumor burden patients should be monitored for tumor lysis syndrome, a serious condition that requires proactive management.
• Be alert for any immediate allergic reactions like facial swelling or breathing issues, and stop Pomalyst immediately if these occur.

Side Effects

The use of Pomalyst is linked to a risk of side effects. The most common side effects of Pomalyst may include tiredness, muscle weakness, irregular bowel movements, back pain, difficulty breathing, and nausea. There are also severe risks associated with its use, such as the formation of blood clots, which may lead to heart attacks or strokes. In addition, this medication carries potential teratogenic effects in pregnancy. If you notice side effects that are persistent or worsening, promptly consult a medical professional.

References:

1. Pomalyst (Pomalidomide) Product Monograph. Princeton, NJ: Bristol Myers Squibb; 2023.
2. Pomalyst (Pomalidomide) Drug Label Information. Princeton, NJ: Bristol Myers Squibb; 2023.

About Dr. Gerardo Sison (Page Author)

An honors graduate of the University of Florida, Dr. Sison started his pharmacy career in a community setting, extending his services to hospitals and clinics over time. He has also worked in medication therapy management, advising patients on proper medication use for their chronic health conditions. Read More....